Khoury S J, Guttmann C R, Orav E J, Hohol M J, Ahn S S, Hsu L, Kikinis R, Mackin G A, Jolesz F A, Weiner H L
Center for Neurologic Diseases, Brigham and Women's Hospital, Boston, MA.
Neurology. 1994 Nov;44(11):2120-4. doi: 10.1212/wnl.44.11.2120.
We followed 18 multiple sclerosis patients clinically and with repeated brain MRIs with and without gadolinium for over 1 year. Clinical evaluations included scoring on the Kurtzke Expanded Disability Status Scale (EDSS) and the Ambulation Index (AI) scale. There was a significant correlation between the change in EDSS or AI and the change in number of lesions on MRI and between cumulative number of lesions on MRI and cumulative change in EDSS or AI. Our findings support the validity of MRI as a measure of clinical activity and potentially as an objective quantitative outcome measure for assessing response to therapy.
我们对18例多发性硬化症患者进行了为期1年多的临床随访,并对其进行了多次脑部磁共振成像(MRI)检查,包括使用和不使用钆对比剂的情况。临床评估包括库尔特克扩展残疾状态量表(EDSS)评分和步行指数(AI)量表评分。EDSS或AI的变化与MRI上病灶数量的变化之间,以及MRI上病灶的累积数量与EDSS或AI的累积变化之间存在显著相关性。我们的研究结果支持MRI作为临床活动度量指标的有效性,并且有可能作为评估治疗反应的客观定量结果指标。